{"name":"YSOPIA Bioscience","slug":"ysopia-bioscience","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQbGdvVFdOQkQyQ016WmtQQ2ZTRU81cWE1VnFFNnFMd2t5bU41Nzh6UURXcVk1YkRHWGkxYlFsMzU1U3VKYnBobGgxSUNBRXZ2VmZiaXhqUnRsclhZbTBIVURxSlF0UmZDM3I4R2E2M0pqcUdSRTdDdDlJdi16QjBCZWU2SzJlalVnXzd1M2kyVFVBaDZ0Rmp1ZlBDeEUtY0FSOHUzN1hiSjAtSWdXN1NWQnZDTE9nbXJGb1VSUkdEQmJFV1ZTcTRkb3lVMVFkcWJyM1ljQTBYSWh1M3BwaTBoMFFVYWJuRHNTYlNjNA?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire UK","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire UK","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNZjVyUVRCNTZDcUxOYlNzd1dRSWZrUE1Qdlh1cEVNY2VHT0c0YU93U1ZuVnpCbzBlMDBkcUxGeHlFbktQbmhaQmpLOGF4bm92cDUxbHpTLUtlbzJ2amVnVy1ieXlsWElUcDRWQ0pYc1Q1N2c1R3hzS1lGcTM4R3dIV1hyTS1Ma0JCRlc5MGduX3V0REYxOVN3QmUwSVFReUVVX3VaUUV3SUJsTGlZTzYtZmFua0NIUnprUmp1V1N0amtUOHNzMTZPbEdQQkhpZ3NnYVI3cENlY25CcXktR3dmaFR0aGIzUExRaE95WmYwRzk1b0kzenNaLWVRMVk5Zw?oc=5","date":"2025-02-27","type":"pipeline","source":"GlobeNewswire","summary":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight - GlobeNewswire","headline":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNc0syVWhkYnNhMFVHRTJxQkR4SjlsUE13VjVndUpwUnFVQVpTNF9xUFppckVVa3plMFFfd2FmdUdaRjRwR3ltR0lvSmlJZzdvY3h0RWdtZ2t2NXVpUkxOdml1dS1ZRGluemtOYXFUNTg2aDd2ZWNVX1drdHN1eGVPWkwtRQ?oc=5","date":"2024-10-16","type":"pipeline","source":"MedPage Today","summary":"Novel Drug Maintained Clinical Improvements in IBD - MedPage Today","headline":"Novel Drug Maintained Clinical Improvements in IBD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOZF9HR0cwWTltNmtaWGNhQ0JxbUxDaF8tdWhIZHRYRUg2NkpzUUFReU5MSGRTcy05QU55cFpYZ1VPLS1YV2hWeUdQOXl5dlRwbDNUek5iOUVGU01KSVMyd3k3dkFjeDdDQXgtTDRidlFuNW5UcHJXNHlRRTZSZm1zX0lsYzBfTmJPaWFuUUowaWJIbWxWZE1idHBWak9leWpBLTFzNUdLX18wcjkyaFlfT2JIbkFZTGViTndzSHJZQ3pWX01xeTRCV1hhRTlOQXNwZVVIM1llS1dsLWJwTXRpLW9sbW5MWUV3SmRxR1VESVJ4amJ3THRnTm9OcHdsV1ZsTHlzYjhOU2dCZGpDUkNQT3o2X0d2My1QakpfVTN0X3c4elN1a2FtdnN0ZXk4dw?oc=5","date":"2024-08-06","type":"trial","source":"GlobeNewswire","summary":"Obesity Clinical Trial Pipeline Appears Robust With 80+ Key - GlobeNewswire","headline":"Obesity Clinical Trial Pipeline Appears Robust With 80+ Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQTUIzUjVWZWgyUEd3ZUlPby00TTAtT2hvUW1jcFdWT0Ixei1BSXRadTRQY3ZCZnI4ZVlFUlY3bGpnMUtVaURBbFpjMy1YVEF1aEhZTWUxTkJXdlRVeTlDOEtWb0hIVFJfbEhPa0VvU3dZME1mS3ZYM1RmeGJqLTdKc1ZHNjZVbDdiNjNNVw?oc=5","date":"2024-06-26","type":"regulatory","source":"Frontiers","summary":"Entering First-in-Human Clinical Study With a Single-Strain Live Biotherapeutic Product: Input and Feedback Gained From the EMA and the FDA - Frontiers","headline":"Entering First-in-Human Clinical Study With a Single-Strain Live Biotherapeutic Product: Input and Feedback Gained From ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-18","type":"pipeline","source":"PR Newswire","summary":"Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Bios","headline":"Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQZkQySzJTa3g3SmxiT2pIOHZfVEhPRGtNS2hMdlktcFhWT3VNZFJIb2ZGMnFBSzNKdDBjNWt5STJYa3pGQVVhbWVCOThwMlQxZ1ZWN2s2bmtoLUVMeV8zWDJiMTdWWmhaTmV4V0pCYXRldWJ5WF9DbGVpWlJDUHZfNXpQUFJNRFVjQmRLWnQyTnJHd213NlREczNRa2pWUTZGa3JHbVVQZk9nNVFwOEl0TVdrYkFjNmlFblBJaGFVNzNZbEcxd2ZFd1BWYkowVE9FdmJkRFdR?oc=5","date":"2023-06-13","type":"pipeline","source":"PR Newswire","summary":"Verb Biotics announces acquisition of YSOPIA Bioscience health and wellness strains - PR Newswire","headline":"Verb Biotics announces acquisition of YSOPIA Bioscience health and wellness strains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE15ZHpMalRyUEFyeFJfNTJyRUJMX1VCVFQ2X0lCU3dHTmd5OXlJT0RhcGhuck85SFBPcm5JN0tmeGE4Zlc5dXAzN2JIWGo4ZXN2c0ZjVnhMTQ?oc=5","date":"2021-10-29","type":"pipeline","source":"EurekAlert!","summary":"Christensenella minuta, a promising LBP cadidate being developed by YSOPIA Bioscience [IMAGE] - EurekAlert!","headline":"Christensenella minuta, a promising LBP cadidate being developed by YSOPIA Bioscience [IMAGE] - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBpelJiWWR0NnR1MU9KRzJDSmtOMGViQWloSjF3LVgxYVNsNmptVF9YWmhIbm0xLXU2QVE3eExlTHhkNGFzQ2JJdGh4U3AtN2prT2NQb1lCdkVNZGM?oc=5","date":"2021-09-09","type":"pipeline","source":"EurekAlert!","summary":"EU, US regulators apply similar mindset when advising live biotherapeutic product developer - EurekAlert!","headline":"EU, US regulators apply similar mindset when advising live biotherapeutic product developer - EurekAlert!","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}